These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 34660511)
1. R&D Investments, Debt Capital, and Ownership Concentration: A Three-Way Interaction and Lag Effects on Firm Performance in China's Pharmaceutical Industry. Su CY; Guo YN; Chai KC; Kong WW Front Public Health; 2021; 9():708832. PubMed ID: 34660511 [TBL] [Abstract][Full Text] [Related]
2. Institutional investors and cost of capital: The moderating effect of ownership structure. Huo X; Lin H; Meng Y; Woods P PLoS One; 2021; 16(4):e0249963. PubMed ID: 33831116 [TBL] [Abstract][Full Text] [Related]
3. Research on the impact of technology mergers and acquisitions on corporate performance: an empirical analysis based on China's pharmaceutical industry. Yang J; Li J; Wang S; Chen Y Front Public Health; 2024; 12():1419305. PubMed ID: 39185128 [TBL] [Abstract][Full Text] [Related]
4. Public funding and private investment for R&D: a survey in China's pharmaceutical industry. Qiu L; Chen ZY; Lu DY; Hu H; Wang YT Health Res Policy Syst; 2014 Jun; 12():27. PubMed ID: 24925505 [TBL] [Abstract][Full Text] [Related]
5. Sovereign wealth fund investments and financial performance of target firms: The disciplinary role of debt in political agenda theory. Rasheed S; Adeneye Y; Kosnin R Heliyon; 2023 May; 9(5):e15519. PubMed ID: 37144204 [TBL] [Abstract][Full Text] [Related]
6. Reducing carbon emissions at the expense of firm physical capital investments and growing financialization? Impacts of carbon trading policy from a regression discontinuity design. Liu H; Pan H J Environ Manage; 2024 Apr; 356():120577. PubMed ID: 38484596 [TBL] [Abstract][Full Text] [Related]
7. Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms' R&D Investment in China? An Event Study Approach. Hu Y; Chen S; Qiu F; Chen P; Chen S Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831803 [TBL] [Abstract][Full Text] [Related]
8. China's Outward Direct Investment in the United States: From the perspective of agglomeration economies. Liang X; Wang J; Lin B; Cao X; Si Y PLoS One; 2022; 17(6):e0269602. PubMed ID: 35687568 [TBL] [Abstract][Full Text] [Related]
9. Will China's R&D investment improve green innovation performance? An empirical study. Fan J; Teo T Environ Sci Pollut Res Int; 2022 Jun; 29(26):39331-39344. PubMed ID: 35099703 [TBL] [Abstract][Full Text] [Related]
10. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments. Han E; Kim TH; Jeung MJ; Lee EK Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327 [TBL] [Abstract][Full Text] [Related]
11. Investment analysis of the private firm under different financial arrangements in infrastructure projects. Ding Q; Huang S; Fu G; Wang B PLoS One; 2024; 19(2):e0287418. PubMed ID: 38363762 [TBL] [Abstract][Full Text] [Related]
12. Governance, financial development and China's outward foreign direct investment. Gao C; Wen Y; Yang D PLoS One; 2022; 17(6):e0270581. PubMed ID: 35771853 [TBL] [Abstract][Full Text] [Related]
13. The nexus between capital structure, firm-specific factors, macroeconomic factors and financial performance in the textile sector of Pakistan. Ullah A; Pinglu C; Ullah S; Zaman M; Hashmi SH Heliyon; 2020 Aug; 6(8):e04741. PubMed ID: 32895635 [TBL] [Abstract][Full Text] [Related]
14. Does university-industry collaboration improve firm productivity? Evidence from China. Li Y; Li Z; Liu T PLoS One; 2024; 19(7):e0305695. PubMed ID: 39079154 [TBL] [Abstract][Full Text] [Related]
15. Green credit, environmental protection investment and debt financing for heavily polluting enterprises. Ji L; Jia P; Yan J PLoS One; 2021; 16(12):e0261311. PubMed ID: 34910790 [TBL] [Abstract][Full Text] [Related]
16. China's Insurance Regulatory Reform, Corporate Governance Behavior and Insurers' Governance Effectiveness. Li H; Zhang H; Tsai SB; Qiu A Int J Environ Res Public Health; 2017 Oct; 14(10):. PubMed ID: 29039781 [TBL] [Abstract][Full Text] [Related]
17. The causal effect on firm performance of China's financing-pollution emission reduction policy: Firm-level evidence. Zhang D; Vigne SA J Environ Manage; 2021 Feb; 279():111609. PubMed ID: 33218832 [TBL] [Abstract][Full Text] [Related]
18. Can capital markets identify heterogeneous environmental investment strategies of firms? Evidence from China. Cheng H; Feng Y Environ Sci Pollut Res Int; 2023 Apr; 30(20):58253-58275. PubMed ID: 36977868 [TBL] [Abstract][Full Text] [Related]
19. Comparison of external R&D and internal R&D: Based on the perspective of S&T development of China's pharmaceutical manufacturing industry. Wu D; Wang S; Chang S; Lian G; Chen Y PLoS One; 2022; 17(6):e0270271. PubMed ID: 35731793 [TBL] [Abstract][Full Text] [Related]
20. Research on U-shaped relationship between short-term debt for long-term use and supply chain enterprise default risk: Evidence from Chinese listed firms. Shen H; Chen J PLoS One; 2023; 18(10):e0293284. PubMed ID: 37871103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]